Invivyd (IVVD) Cash & Equivalents (2020 - 2025)
Invivyd (IVVD) posted Cash & Equivalents of $226.7 million for Q4 2025, up 166.8% on a QoQ basis from $85.0 million in Q3 2025, and up 226.88% year-over-year from $69.3 million in Q4 2024.
Invivyd (IVVD) Cash & Equivalents (2020 - 2025) Analysis & Trends
Invivyd's Cash & Equivalents history runs 6 years deep, the most recent figure standing at $226.7 million for Q4 2025.
- Quarterly Cash & Equivalents rose 226.88% year-over-year to $226.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $226.7 million (up 226.88% YoY) and the FY2025 annual result came in at $226.7 million, up 226.88% from the prior year.
- Cash & Equivalents was $226.7 million for Q4 2025 at Invivyd, up from $85.0 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $542.2 million in Q4 2021 and bottomed at $34.9 million in Q2 2025.
- A 5-year average of $227.9 million and a median of $181.8 million in 2023 frame the typical range for Cash & Equivalents.
- Annual changes were most pronounced in 2021 — Cash & Equivalents jumped 371.55% — and 2022, when it tumbled 83.02%.
- Invivyd's Cash & Equivalents stood at $542.2 million in 2021, then tumbled by 83.02% to $92.1 million in 2022, then surged by 117.91% to $200.6 million in 2023, then plunged by 65.44% to $69.3 million in 2024, then jumped by 226.88% to $226.7 million in 2025.
- Business Quant data shows IVVD's Cash & Equivalents at $226.7 million in Q4 2025, $85.0 million in Q3 2025, and $34.9 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 82.45 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 61.40 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 2.83 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 4.79 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 5.49 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 2.96 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 3.58 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 440.94 Mn |
| 10 | Invivyd | 104.07 Mn | -122.62 Mn | 16.07 Mn | 226.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 226.69 Mn |
| Sep 30, 2025 | 84.97 Mn |
| Jun 30, 2025 | 34.91 Mn |
| Mar 31, 2025 | 48.08 Mn |
| Dec 31, 2024 | 69.35 Mn |
| Sep 30, 2024 | 106.87 Mn |
| Jun 30, 2024 | 147.88 Mn |
| Mar 31, 2024 | 189.39 Mn |
| Dec 31, 2023 | 200.64 Mn |
| Sep 30, 2023 | 181.82 Mn |
| Jun 30, 2023 | 121.95 Mn |
| Mar 31, 2023 | 126.47 Mn |
| Dec 31, 2022 | 92.08 Mn |
| Sep 30, 2022 | 278.15 Mn |
| Jun 30, 2022 | 474.89 Mn |
| Mar 31, 2022 | 532.22 Mn |
| Dec 31, 2021 | 542.22 Mn |
| Sep 30, 2021 | 478.27 Mn |
| Jun 30, 2021 | 392.51 Mn |
| Dec 31, 2020 | 114.99 Mn |